Alpha-synuclein immunotherapy
Active and passive immunotherapies (prasinezumab, cinpanemab, UB-312) targeting pathological alpha-synuclein.
State of the art
No update yet for Alpha-synuclein immunotherapy. An update is a standalone state-of-the-art for the topic — what someone with Parkinson's needs to know about where this approach stands today.
No reader summaries on this topic yet.